- Home
- WKSP vs TPST Comparison
WKSP vs TPST Comparison
Compare WKSP & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WKSP | TPST |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 15.6M |
| IPO Year | 2015 | 2012 |
Fundamental Metrics
Financial Performance| Metric | WKSP | TPST |
|---|---|---|
| Price | $0.68 | $1.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $9.25 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 309.4K | 204.4K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.89 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,101,738.00 | $295,000.00 |
| Revenue This Year | $131.96 | N/A |
| Revenue Next Year | $24.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 89.78 | N/A |
| 52 Week Low | $0.57 | $0.84 |
| 52 Week High | $4.30 | $12.22 |
Technical Indicators
Market Signals| Indicator | WKSP | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 45.55 | 69.31 |
| Support Level | $0.58 | $1.02 |
| Resistance Level | $0.77 | $2.48 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 53.25 | 90.47 |
Price Performance
Historical ComparisonAbout WKSP Worksport Ltd.
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers. It operates in two reporting segments for financial reporting purposes: Hard Tonneau Covers and Soft Tonneau Covers. Geographically, the company operates in Canada, United States and Other Countries.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.